Bell Potter Sticks to Its Buy Rating for Impedimed Limited (IPDQF)
I'm PortAI, I can summarize articles.
Bell Potter's Martyn Jacobs maintains a Buy rating for Impedimed Limited (IPDQF) with a price target of A$0.07. Jacobs, who covers the Healthcare sector, has an average return of -20.1% and an 11.01% success rate on recommended stocks. The analyst consensus for Impedimed Limited is a Moderate Buy with an average price target of $0.07.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments